These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21538468)

  • 1. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
    Ganesan P; Sagar TG; Dubashi B; Rajendranath R; Kannan K; Cyriac S; Nandennavar M
    Am J Hematol; 2011 Jun; 86(6):471-4. PubMed ID: 21538468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
    Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
    Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
    Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
    Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
    Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
    J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
    White DL; Dang P; Engler J; Frede A; Zrim S; Osborn M; Saunders VA; Manley PW; Hughes TP
    J Clin Oncol; 2010 Jun; 28(16):2761-7. PubMed ID: 20421539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
    Qin Y; Jiang B; Jiang Q; Jiang H; Li J; Zhang Y; Zhu H; Li L; Chen S; Liu Y; Huang X
    Ann Hematol; 2009 Jan; 88(1):37-41. PubMed ID: 18651143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
    Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
    N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib].
    Wang GR; Zhao YZ; Qian LS; Zou DH; Li R; Mi YC; Wang XX; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):18-22. PubMed ID: 18512310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
    Zaritskiĭ AIu; Lomaia EG; Vinogradova OIu; Druzhkova GA; Kolosheĭnova TI; Loria SS; Pospelova TI; Krylova IV; Kruglov SS; Kuznetsov SV; Chelysheva EIu; Abakumov EM; Sokolova MA; Nemchenko IS; Zakharova ES; Goriacheva SR; Kolosova LIu; Vakhrusheva MV; Liamkina AS; Chernova OA; Machiulaĭtene ER; Ivanova VL; Udal'eva VIu; Shneĭder TV; Ogorodnikova IuS; Zhuravlev VS; Zakharova AV; Martynkevich IS; Domracheva EV; Afanas'ev BV; Abdulkadyrov KM; Kovaleva LG; Khoroshko ND; Turkina AG
    Ter Arkh; 2007; 79(8):17-22. PubMed ID: 17926465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
    Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
    Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
    Nardinelli L; Sanabani SS; Didone A; Ferreira Pde B; Serpa M; Novaes MM; Marchiani M; Ruiz AL; Lima IS; Chamone Dde A; Bendit I
    Acta Haematol; 2012; 127(4):228-34. PubMed ID: 22508387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.